CURI — Insider Trading Activity
One insider at CURI put personal money into the stock on the open market this window, led by the CEO, with nobody selling.
What this means for CURI
CURI is not showing a cluster buy or a step-change versus its own baseline, so what the window amounts to is a single insider acting alone. Who is buying. The most credible buyer in this window is the company’s CEO ($100K–$500K), growing their stake by 2%. That insider’s track record: past buys beat the S&P 500 2 of 2 times (avg +132% vs S&P over 6 mo). Overall credibility score: 36/100 (Low).
By the numbers. One insider filed 2 open-market purchases at CURI over the window, 50,000 shares in all at an average of $2.57 a share, most recently on August 28, 2026. No insider sold CURI stock on the open market in that period.
How we read these filings — which transaction codes count, how the cluster and credibility thresholds are set, and what the signals have and haven’t predicted — is written up in the insider trading methodology.
CURI insider filings, one by one
All 2 Form 4 filings from the last 90 days, by insider, with share count, dollar amount and date.
Other tickers with the same signal
Companies of a comparable size whose Form 4 filings tripped the same insider buying flag as CURI in this window.
- LAW insider trading — 1 buyer, 4 sellers, credibility 16/100
- GAIA insider trading — 1 buyer, credibility 20/100
- ACON insider trading — 6 buyers, credibility 31/100
- FLNC insider trading — 2 buyers, credibility 24/100
- EVRG insider trading — 1 buyer, credibility 21/100